{"id":"W4404368241","doi":"10.1016/j.jaad.2024.10.076","title":"FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis","year":2024,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"Cilag; Galderma; Janssen Research and Development; Pfizer Pharmaceuticals; LEO Pharma; Bausch Health; Basilea Pharmaceutica; Glenmark Pharmaceuticals; Actelion Pharmaceuticals; Pfizer; Biogen; Incyte; IC Design Education Center; Kiniksa Pharmaceuticals; Regeneron Pharmaceuticals; Mylan; Castle Biosciences; Dermira; Celgene; Valeant Pharmaceuticals International; Sanofi; Amgen; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Plaque psoriasis; Term (time); Dose-ranging study; Dermatology; Psoriasis; Extension (predicate logic); Internal medicine; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001370573,0.001328613,0.000877569,0.0003603559,0.0002999719,0.0006659958,0.0007642388,0.0007978354,0.004665422],"category_scores_gemma":[0.0004311777,0.0003928525,0.000655175,0.0002184219,0.0005839284,0.000570593,0.0003213615,0.002329588,0.0009448909],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000538561,"about_ca_system_score_gemma":0.001222255,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000814867,"about_ca_topic_score_gemma":0.002196391,"domain_scores_codex":[0.9997638,0.0000875925,0.000009565751,0.0000364995,0.00004597629,0.00005664405],"domain_scores_gemma":[0.9996591,0.00005371495,0.00008129665,0.00001855475,0.00002435246,0.0001630559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4196254,0.137373,0.009271151,0.002472741,0.001254542,0.0006449926,0.0004395378,0.002519731,0.2261628,0.000643165,0.01003763,0.1895553],"study_design_scores_gemma":[0.560154,0.3961386,0.02603768,0.0001030153,0.000469519,0.0007672129,0.00007933666,0.0009388581,0.01011043,0.0001754374,0.0049809,0.00004508064],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923919,0.002499444,0.000492172,0.0003658883,0.00008304349,0.001440797,0.0008374383,0.0001051679,0.001784187],"genre_scores_gemma":[0.9857757,0.00268408,0.001943062,0.0008988304,0.0001742261,0.001544319,0.002191291,0.00004031503,0.004748193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004665422,"threshold_uncertainty_score":0.01560742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03348407815273174,"score_gpt":0.3308613464931109,"score_spread":0.2973772683403791,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}